Sydney, Australia – 15 September 2025 — GlyTherix, a leading Australian radiopharmaceutical company developing antibody-based therapeutics for the treatment of solid tumors, is proud to announce its participation as an Industry Partner in the Australian Research Council (ARC) Training Centre for Development of Advanced Radiochemical Technologies (DART) (https://arcdart.org/).
DART is a nationally funded research centre led by Monash University in partnership with leading academic institutions and industry collaborators. The Centre is designed to accelerate innovation in radiopharmaceutical science and foster the next generation of experts in radiochemistry, radiobiology, and molecular imaging.
As an industry partner, GlyTherix will contribute its proprietary monoclonal antibody platform to advance the development of targeted radiopharmaceutical therapies. In addition to scientific collaboration, the company will help guide translational research efforts and support PhD training programs aimed at equipping students with the skills needed to bring novel therapies from bench to bedside.
GlyTherix’s involvement will be led by Dr. Yanling Lu, Head of Chemistry, Manufacturing and Control (CMC) at GlyTherix and now a member of the Executive Committee within the DART Centre. Dr. Lu brings extensive expertise in biopharmaceutical manufacturing and radioconjugate development, and will play a key role in supervising joint research projects between GlyTherix and academic partners.
“We are honoured to be part of the DART initiative and excited to contribute to this dynamic ecosystem,” said Dr. Brad Walsh, CEO of GlyTherix. “With Dr. Yanling Lu leading our scientific efforts within DART, we’re confident that this partnership will accelerate the development of novel radiopharmaceuticals to improve outcomes for cancer patients worldwide.”
“This collaboration provides an excellent platform to combine academic innovation with industrial translation,” said Dr. Yanling Lu. “I look forward to mentoring emerging researchers and advancing next-generation targeted radiotherapies through this unique program.”
This partnership reinforces GlyTherix’s strategic focus on precision oncology, combining monoclonal antibody technology with advanced radiochemical modalities. It also underscores the company’s commitment to scientific excellence, workforce development, and positioning Australia as a global leader in radiopharmaceutical research.